FDA ap­proval lets Foamix set its maid­en ac­ne ther­a­py on course for US mar­ket launch

Months ago, Foamix leaned on its biggest share­hold­ers — Per­cep­tive Ad­vi­sors and Or­biMed — to fi­nan­cial­ly grease its wheels, ahead of the FDA de­ci­sion date for its ac­ne ther­a­py. On Fri­day, that ap­proval came in — and the top­i­cal for­mu­la­tion of the an­tibi­ot­ic minocy­cline is set for a Jan­u­ary launch.

The ther­a­py, Amzeeq (for­mer­ly known as FMX101), was ap­proved to treat in­flam­ma­to­ry le­sions of non-nodu­lar mod­er­ate-to-se­vere ac­ne vul­garis in pa­tients aged 9 and old­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER